Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. [electronic resource]
- Brain research Feb 2006
- 209-19 p. digital
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
0006-8993
10.1016/j.brainres.2005.12.014 doi
Adrenergic Agents--toxicity Analysis of Variance Animals Autoradiography--methods Brain--drug effects Brain Chemistry--drug effects Chromatography, High Pressure Liquid--methods Disease Models, Animal Dopamine--metabolism Dose-Response Relationship, Drug Drug Interactions Electrochemistry--methods Gene Expression--drug effects Glutamic Acid--metabolism In Situ Hybridization--methods Injections, Intraventricular--methods Male Motor Activity--drug effects Oxidopamine--toxicity Parkinson Disease--drug therapy Piperidines--therapeutic use Protein Binding--drug effects Pyrazoles--therapeutic use RNA, Messenger--metabolism Rats Rats, Sprague-Dawley Reaction Time--drug effects Receptor, Cannabinoid, CB1--antagonists & inhibitors Rimonabant Rotarod Performance Test--methods Superoxide Dismutase--genetics Superoxide Dismutase-1 Tyrosine 3-Monooxygenase--genetics gamma-Aminobutyric Acid--metabolism